Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 50,319 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignancies Clear all
Active, not recruiting Phase 2 Interventional

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

NCT04505254
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Obinutuzumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Withdrawn Phase 1 Interventional

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

NCT03422874
View directory record Official record
Conditions
Neoplasms, Lymphoma
Interventions
MLN9708, Nelfinavir
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities

NCT01544374
View directory record Official record
Conditions
Breast Cancer
Interventions
Tracking & Feedback
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Newark, New Jersey • Brooklyn, New York • Elmhurst, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Opening the Conversation Study

NCT04806724
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
Opening the Conversation, Side by Side
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional Results available

Dasatinib In Waldenström Macroglobulinemia

NCT04115059
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, DASATINIB
Interventions
Dasatinib
Drug
Lead sponsor
Jorge J. Castillo, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Game-Based Physical Activity in Childhood Cancer Survivors

NCT04266080
View directory record Official record
Conditions
Survivors of Childhood Cancer
Interventions
Fitbit Inspire HR, Questionaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
10 Years to 16 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

NCT00495079
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Marqibo® (vincristine sulfate liposomes injection)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of TRC105 and Sorafenib in Patients With HCC

NCT02560779
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Carotuximab (TRC105), Sorafenib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

NCT06237179
View directory record Official record
Conditions
Prostate Cancer, Supportive Care
Interventions
Exercise Training Intervention, Healthy Living Education
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

NCT04150562
View directory record Official record
Conditions
Clear-Cell Renal Carcinoma
Interventions
rhIL-15, Avelumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 25, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)

NCT05375162
View directory record Official record
Conditions
Cancer
Interventions
Core Intervention, E-Coach, General Mindfulness Training, MVPA-Specific Mindfulness Training, Buddy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 39 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

NCT01348503
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lenalidomide, Sorafenib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 25, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

Axoguard HA Plus Nerve Protector to Reduce Post-operative Neck and Shoulder Dysfunction in Patients Undergoing Neck Dissection

NCT07283861
View directory record Official record
Conditions
Head and Neck Cancer, Neck Dissection
Interventions
Spinal Accessory Nerve Protection utilizing Axoguard HA+
Device
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

eMOTION: Examining Affective Mechanisms in Physical Activity Engagement

NCT06570642
View directory record Official record
Conditions
Physical Inactivity, Overweight or Obesity, Cancer
Interventions
Physical Activity Goals mHealth Intervention, TYPE/CONTEXT enhancement, SAVOR enhancement
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT06974786
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord

NCT00631670
View directory record Official record
Conditions
Spinal Tumors
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers

NCT03902535
View directory record Official record
Conditions
Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Lung Carcinoma, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

NCT03003468
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Imprime PGG, MK-3475
Drug
Lead sponsor
Lawrence Feldman, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Creatine in Treating Patients With Cancer-Associated Weight Loss

NCT00081250
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
Interventions
creatine monohydrate, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
220
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 139 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 25, 2026, 4:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

NCT05852691
View directory record Official record
Conditions
Breast Cancer
Interventions
Tobemstomig, Pembrolizumab, Nab-Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Alamitos, California • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer

NCT00089310
View directory record Official record
Conditions
Lung Cancer
Interventions
technetium-99
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
12
States / cities
Lewes, Delaware • Newark, Delaware • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Phase 1 Interventional

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

NCT03081910
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 4:42 PM EDT